Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Alexander Schmitz1,2, Rasmus Froberg Brøndum1,2, Hans Erik Johnsen1,2,3,4∗, Ulf-Henrik Mellqvist4,5, Anders Waage6,7, Peter Gimsing4,7, Davine Hofste op Bruinink8, Vincent van der Velden8, Bronno van der Holt8,9, Markus Hansson4,10, Niels Frost Andersen4,11, Ulf Christian Frølund4,12, Carsten Helleberg4,13, Fredrik H. Schjesvold9,14,15, Lucia Ahlberg4,16, Nina Gulbrandsen4,14,15, Bjorn Andreasson4,17, Birgitta Laur4,18, Einar Haukas4,19, Julie Støve Bødker1,2, Anne Stidsholt Roug1,2,3, Martin Bøgsted1,2,3, Marianne T. Severinsen1,2, Henrik Gregersen1,2,3, Niels Abildgaard4,20, Pieter Sonneveld8,21 and Karen Dybkær1,2,3∗

Abstract

Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments.

Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression.

Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with ≥3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease progression.
Introduction

Multiple myeloma (MM) is a common malignant gammopathy and associated with a wide spectrum of symptoms [1]. Patients typically present with proliferation of abnormal monoclonal plasma cells (PC) in the bone marrow (BM) and monoclonal protein (M-component) in the serum and/or urine [2]. Therapeutic advancements like autologous stem cell transplant, proteasome inhibitors, immune-modulators and monoclonal antibodies have resulted in significant improvements in treatment response depth and clinical outcome [3]. However, the majority of patients will eventually develop refractory disease, making MM a remaining incurable disease [4].

Precise assessment of response to therapy is of high importance in every phase of MM and consensus recommendations have been developed by the International Myeloma Working Group for uniform reporting of response levels [5]. Complete response is biochemically defined as non-detectable M-component in the serum and urine by immunofixation plus disappearance of any soft tissue plasmacytoma, and detection of <5% plasma cells in BM. Stringent CR (sCR) includes all CR criteria plus a normal ratio of serum free light chain ratio (sFLC) together with the absence of monoclonal PCs by immunohistochemistry after counting ≥100 BM PC or immunofluorescence at a sensitivity level of $10^{-2}$ [6, 7]. Achievement of a normal sFLC ratio is associated with improved outcomes including overall survival [8, 9].

Relapse is a consequence of the expansion of residual MM cells [5]. These residual MM cells in patients may be detectable as “minimal residual disease” (MRD, also referred to as “measurable residual disease”) by current Next Generation Flow (NGF) or VDJ sequencing methods with which a minimal sensitivity level of $10^{-5}$ or $10^{-6}$ can be reached [10, 11]. MRD negativity at the $10^{-5}$ level or even more informative at the $10^{-6}$ level is a strong prognostic factor of progression-free survival and is under consideration as a surrogate trial endpoint to improve the identification of effective treatments [12–15]. Additionally, IMWG guidelines have introduced the term sustained MRD negativity for individuals with MRD negativity confirmed 1 year apart [5].

Multiparametric flow cytometry (MFC) is a widely applicable technique, allowing identification and discrimination between normal and abnormal PCs based on aberrant patterns of protein expression by neoplastic PCs. MFC has been reported to hold diagnostic, prognostic and predictive information and plays an increasingly important role in diagnostics and prognostics of plasma cell disorders [16, 17]. Flow-MRD assessment, the evaluation of absence of phenotypically aberrant PCs using MFC, currently reaches method sensitivities between $10^{-4}$ and $10^{-6}$ [11].

Treatment of other haematological malignancies, such as acute lymphoblastic leukaemia and chronic myeloid leukaemia, often are guided by MRD results, and achievement of MRD negativity has been endorsed as a purpose the treatment in acute myeloid leukaemia [18–20]. However, standardization of MRD testing in MM as well as defining the role of MRD status in guiding treatment decisions remains unanswered and is ongoing [21]. We hypothesized that longitudinal BM flow-MRD measurements would reveal information on depth and dynamics of MRD that potentially could drive treatment decisions and tailor therapeutic strategies in the future. Few studies have longitudinally evaluated MRD in MM [22–24]. Therefore, we aimed to investigate the impact of long-term sequential BM flow-MRD assessments to determine the potential of flow-MRD monitoring in comparison to standard disease monitoring by M-component and sFLC ratio.

Methods

Study Design: The NMSG MRD substudy was part of the EMN02/HO95 trial (NCT01208766) and enclosed 23 sites from the Nordic countries [25]. Patients were included in the study from March 1, 2012 to March 31, 2014. Patients undergoing BM aspiration for response assessment prior to start of maintenance treatment were eligible for the MRD study [26]. The study was approved by the national and regional committees (see supplementary information for detailed list) on health research
ethics and performed in accordance with the good clinical practice regulations and the declaration of Helsinki principles with written informed consent from all included patients.

Specimens and clinical data: Heparin-stabilized BM samples were received (at the NMSG central Biobank at Aalborg University Hospital) for MFC analysis at diagnosis and were, when eligible for the MRD-study, subsequently for molecular response assessment by flow cytometry (1st flow-RA) and following flow-MRD analyses (Table S1). The EMN Data Center (Torino/Italy) had collected data on clinical characteristics, namely dates for inclusion (INCL), clinical response status (RS) and 1st progression, as well as biochemical analysis data including serum protein electrophoresis (SPEP), serum immunofixation (IF) status, and sFLC ratio. Presence of an M protein on SPEP or IF were considered as positive; sFLC ratios outside the 0.26–1.65 range as abnormal [7]. Clinical progression and RS were documented from the participating sites and defined according to IMWG criteria [27, 28]. Reasons for end of follow-up was death, emigration, patients withdrawal from study participation (off-protocol), or October 31st, 2018 (cut-off) for the flow cytometric data. Cut-off for the clinical data was set at September 18th, 2019. Clinical progression and overall survival status were matched to censoring date for data comparability with the flow-MRD data.

Flow-MRD assessment: A modified 1st generation Euroflow antibody 2 tube panel set for PC disorders (PCD) was applied to freshly stained BM aliquots [29]. For more detailed information see supplementary information (supplementary methods and Table S2; Fig. S1) and Op Bruinink et al. 2020 [30–35]. Flow-MRD positivity was defined as the enumeration of ≥40 mPC cells among ≥1 × 10⁶ total nucleated cells across all concatenated tubes, reflecting a minimum detection limit of 4 × 10⁻⁵ (0.004%). Samples with insufficient quality or technical issues were excluded (“inadequate sample”) as outlined in Table 1. Critical parameters for exclusion were total cellularity (<1 × 10⁵ cells for diagnostic samples; <1 × 10⁶ cells for MRD samples), aggregation, coagulation, haemodilution, absence of a clear defined mPC population (<0.1% for diagnostic samples), absence of a nPC population (for MRD samples, <100 cells), inadequate specimen processing and/or technical issues. Only samples analysed within 52 h after sampling were included into the MRD-analysis, as recommended from current literature [36, 37].

Statistical data analysis: A doubling time for mPC expansion in patients with subsequent biochemical and clinical progression was derived by fitting a log-linear model of mPC versus time and dividing log(2) with the regression coefficient. Differences in proportions were tested using Fishers exact test.

Results
Detection of mPCs in BM samples from patients in CR/SCR at 1st flow-response assessment
During the inclusion period, 136 patients (age range 18–64 years) were registered in the NMSG MRD study (Table 1 Part A). In 53 patients, a BM aspirate sample was sent for a first response assessment by flow cytometry (1st flow-RA), when assumed to be in CR/SCR at any time during the course. Fifteen patients with confirmed clinical response status of CR or better (12 with sCR; 3 with CR) and an adequate BM sample were included in the 1st flow-RA analysis (Table 1 Part B; Table S3; Fig. 1). Thirty-eight patients were excluded (31 patients with RS<CR, 1 Off-protocol, 6 with inadequate BM samples). Flow-RA revealed, that 80% (12/15) patients with clinical CR/sCR were mPC negative. Eleven of these patients were in sCR. In the remaining three patients (20%) a small mPC population (64, 126 and 4319, respectively) was detected. Frequency range was 8.2 × 10⁻⁴ to 8.8 × 10⁻⁵ mPC/10⁶ cells. Corresponding sFLC ratios were normal in the three patients (Fig. 1). Time from inclusion to 1st flow-RA varied widely (interval range 2.7–41.6 month, median 20.1 months; lower quartile: 12.6 month; upper quartile: 35.4 months), and sample size varied greatly from 1.3–13.4 × 10⁶ acquired cells (median 5.9 × 10⁶). Due to the small size of the dataset with three flow-RA positive patients, no statistical conclusion could be drawn for rate of clinical progression between the two groups. However, all three flow-RA positive patients subsequently progressed.

Flow-MRD identifies early progression
Longitudinal flow-MRD assessments were carried out to determine the potential of flow-MRD monitoring on the risk of disease progression and to evaluate its dynamics. The inclusion criterium for this long-term analysis was the achievement of CR during the patient’s course, thereby including patients with VGPR or better at first response assessment. As outlined (Table 1 Part C; Table S3), 34 patients from 53 patients included in the MRD-study fulfilled these criterium, of which 19 patients have been in CR at 1st RA. This group comprises the same 15 patients from the 1st flow-RA analysis plus 4 patients, where 1st flow-RA was not available, but subsequently BM samples for flow-MRD assessment were received. Accordingly, 19 patients (19/53) were excluded (15 patients with best RS of VGPR or lower, 6 patients with only inadequate BM samples, 2 patients went off-protocol).
For 20 patients (20/34) at least three flow-MRD assessment points with adequate BM samples were analysed (Table 1 Part C; Table S3; Fig. 2). Of these 20 patients, 13 patients displayed sustained flow-MRD negativity upon acquisition of $1.2 \times 19.5 \times 10^6$ cells (mean $7.1 \times 10^6$, $N = 105$), accompanied by normal values for SFLC ratio, SPEP and IF; and they all remained clinical progression free within the observation period of 6 years (non-progressors). One patient developed extra medullary disease without BM involvement.

Six patients progressed in the BM (progressors). Longitudinal flow-MRD evaluation revealed flow-MRD positivity followed by mPC population increase for all six progressors upon 3–13 sequential follow-up samples (Median evaluation interval 3.8 months, range 1–30 months; Fig. 3, Table S4). Mean mPC doubling time for the six patients was calculated to be 1.8 months with a confidence interval of 1.4 to 2.3 months, assessed by fitting a log-linear model with the mPC concentration versus time to progression (Fig. 3). Flow-MRD positivity was observed with a median of 12.6 months (IQR 11.8 month, 6 patients) before clinical progression was recorded, and 5.5 months (IQR 9.3, 5 patients) before biochemical parameters became abnormal, which were recurrence of abnormal sFLC ratio in 4 patients and positive SPEP in one patient (Table S2). In patient PID124 all analysed biochemical parameters remained normal until clinical progression.
Discussion

The primary objective of the flow-MRD study was to evaluate the depth and dynamic of flow-MRD and the risk of disease progression in MM patients in posttreatment CR during lenalidomide maintenance. Our data confirm that flow-MRD is a sensitive tool for response evaluation and subsequent patient monitoring.

First, flow-RA was able to detect residual mPC within the group of patients in CR/sCR, underscoring that flow-RA using the flow-MRD panel has superior sensitivity compared to biochemical and morphological assessment. This observation is in line with previous studies, documenting MRD positivity in MM patients in CR [38, 39]. However, the limited number of patients in the flow-RA positive group did not allow analysis of whether presence of residual mPC at end of treatment evaluation in CR/sCR patients had an impact on progression free survival (PFS) and overall survival (OS) between patients in CR with detectable versus undetectable MRD. These subjects are to be touched upon in upcoming reports for the total EMN02 study [40].

Second, and more important, we determined the prognostic role of MRD by longitudinally monitoring flow-MRD in patients in remission. Focusing on patients with intramedullary disease with achieved CR during the treatment course we showed that MRD appearance, assessed by flow-MRD, predicted biochemical disease progression 5.5 months in advance and 12.6 months in advance to clinical progression. For comparison, in recent studies, where MM patients were sequentially monitored after induction and subsequent autologous stem cell transplantation plus continuous maintenance, a 4-month precedence of MRD appearance was noted [41].

(See figure on next page.)

**Fig. 1** 1st Flow-RA of bone marrow sample received from patients at response evaluation. X-axis: Patients with response status of CR and sCR are aligned according to PID number and flow-MRD status. Y-axis: Cell Counts/sFLCr values (log scale). (*1): sFLCr was close to normal range (0.24) and became normal with the next sFLCr measurement (1.58). (*2): sFLCr was taken 27 days after MFC date, previous sFLCr measurement (>27 days before MFC date) displayed normal ratio. Abbreviations: CR: Complete response. SCR: Stringent complete response. Patient ID / PID: Patient identification number. SFLCr: Serum free light chain ratio. MFC: Multiparameteric flow cytometry. mPC: Malignant plasma cells. nPC: normal polyclonal plasma cells

**Fig. 2** Flow-MRD monitoring of patients reaching CR/sCR during their course, identifies flow-MRD positive patients over time before progression is clinically observed, while flow-MRD negative maintain progression-free regardless their initial RS status. Data points for longitudinal flow-MRD assessment (circles) after inclusion from 20 patients with ≥3 flow-MRD BM samples (inclusive 1st RA), analysed until clinical progression or until date of last clinical contact are lined up over time. Inclusion, RS, progression and date of last contact (until censoring) are indicated. Abbreviations: PR: Partial response. VGPR: Very good PR. CR: Complete response. SCR: stringent CR. INCL: Date of inclusion into the MRD-study. PROG: Date of clinical progression. Flow-MRD: MRD assessment using MFC. RA = Response assessment. RS: Response status (clinical). Patient ID: Patient identification number. SFLCr: Serum free light chain ratio. MFC: Multiparameteric flow cytometry. mPC: Malignant plasma cells. DLC: Date of last contact or censoring date. (*) Patients progressed with extramedullary disease. n.d.: 1st RA BM sample not received or flow-MRD status not determined.
Fig. 2 (See legend on previous page.)
positivity towards biochemical relapse and 9 months to clinical relapse were observed [22, 24]. Furthermore, in a cohort of six patients we observed a mean doubling time of less than 2 months (1.8 months with confidence interval 1.4–2.3 months). To the best of our knowledge, no other studies have calculated the dynamics of mPC expansion during pre-clinical relapse. Together, these observations underscore the potential value of sequential flow-MRD assessments. Loss of MRD negativity is the earliest marker of progressive disease and this information could be clinical useful to help clinicians restart treatment before the occurrence of clinical progression and relapse.

IMWG has previously arbitrarily proposed a 12 months interval for monitoring patients with sustained flow-MRD [5]. In our study, based on three cases (PID45, PID124, PID132), the duration from first assessed flow-MRD negativity to flow-MRD positivity was 22.6 months (mean 11.1, 19.1, 37.7 months). The IMWG proposed 12 months flow-MRD monitoring interval would thus be sufficient for early prediction of progression in 2 out of 3 cases in our study. However, the small number of patients and the wide spread of duration does not allow to draw a meaningful conclusion on a general monitoring interval. Individual patients may differ largely in courses of MRD progression based on risk group, cytogenetic or clonogenic landscape in the malignant cell clones, a larger dataset is needed for robust statistical conclusions [41].

Previously, it was observed, that progressing patients with negative MRD after autologous stem cell transplantation lost their MRD negative status with a median time of 18 months (10 patients), and even shorter intervals of 6 to 12 months for monitoring patients with MRD negative status were suggested [24]. With our observation of a doubling time of 1.8 months for mPC expansion after reaching MRD-positivity, argues for a more frequent flow-MRD monitoring after the initial detection of mPC, to follow their increase in the BM, preceding clinical progression.

Methodologically, the minimum level of flow-MRD detection was defined at study initiation to be $4 \times 10^{-5}$ (0.004%, ≥40 mPC among ≥10⁶ cells), in order to challenge the IMWG recommendation of 0.01% from 2008. However, consensus criteria for flow-MRD negativity was updated in 2016 to a minimum sensitivity of $10^{-5}$, among acquisition of $\geq 3 \times 10^6$ cells [5]. Furthermore, there is now evidence, that patients achieving MRD negativity at the level of $10^{-6}$ have prolonged progression-free periods when compared to those who are MRD negative at $10^{-5}$ or lower [42, 43]. Although we aimed to analyse

**Fig. 3** Monitoring the quantity of flow-MRD until clinical progression across six patients with clinical progression reveals, that flow-MRD positivity precedes substantial changes in clinical monitored values for sFLC, SPEP and IF, and subsequent clinical progression. Time from inclusion to measured flow-MRD positivity varied from 5.9–64.4 month (Mean 19.1 month). MRD positivity was detected with a mean of 1.26 month (range 9.6–26.6) before clinical progression (according to IMWG standard) was recorded. Median mPC doubling time was calculated to 1.8 month (1.4–2.3) across the six patients, fitting a log-linear model for mPC concentration (mPC/×10⁶ events) versus time to clinical progression. X-axis: Timeline (months to clinical progression). Y-axis: mPC frequency. Achieved flow-MRD detection limit for the MRD+ patient group is shown as a dotted horizontal line. Abbreviations: MRD: Minimal residual disease. PID: Patient identification ID. SCR: Stringent complete response. SFLC: Serum free light chain ratio (abnormal/normal). IF: Immunofixation (positive/negative) SPEP: Serum protein electrophoresis (positive/negative). Lin: Linear. Log: Logarithmic. nd: not determined. '0': Flow-MRD negative.
10^6 cells per BM sample, all available cells from an MRD sample were routinely processed, resulting in 65% of BM samples (across 34 patients) and 86% of BM samples (across 20 patients with ≥3 MRD samples processed) with ≥3 × 10^6 cells acquired. However, we find, that the acquisition of 1 × 10^6 events would have been sufficient for the detection and enumeration of MRD-positivity in our patients, and vice versa no clear mPC population was detected in patients with sustained flow-MRD negativity upon acquisition of up to 2 × 10^7 cells (average 7.0 × 10^6 across 110 flow-MRD negative BM samples). This suggests that acquisition of 1–3 × 10^6 events in most cases is sufficient for flow-MRD evaluation, thereby accepting the risk of falsely missing patients with rare residual cells due to sensitivity restrictions in first place in few cases; but those will be detected subsequently when monitored longitudinally.

Achievement of complete response has been accepted as a relevant surrogate marker of survival and attainment of patients attaining sCR has been shown to translate to better survival outcomes compared to conventional CR alone [27, 44]. However, the association between conventional response outcomes and survival in patients with newly diagnosed MM is not clear [45, 46]. Especially, the prognostic value of sFLC measurements in MM patients has been questioned; large studies supporting the role of the assessment and others questioning the role of sFLC in the evaluation of response [47]. In our dataset, flow-MRD negative and non-progressing patients had also normal for sFLC ratios. Among the six progressing patients, we observed changes in the biochemical markers including sFLC ratio in most of the patients (83%), before clinical progression was documented, however, only 50% became sFLC ratio abnormal. These changes were generally detected months later than flow-MRD positivity, underpinning the higher sensitivity of flow-MRD analysis versus biochemical markers, relying on traditional biochemical techniques and plasma cell enumeration by morphology with suboptimal sensitivity. Only PID124 progressed without biochemical abnormality, although flow-MRD detected monoclonal mPC in the BM. It is possible, that this patient has non-secretory malignant cells that may not express and release light chain into the PB at levels detectable with the standard serum measurements. Also measuring M-protein levels are not applicable in patients with oligosecretory or non-secretory disease, because in these cases the levels of the paraprotein are low or nondetectable [48]. To date, there is no uniform association between rapidity of response and survival outcomes in MM. Studies, but performed before introduction of novel agents, have demonstrated that a rapid decrease of M-protein in the first 1 or 2 cycles of therapy is predictive of longer survival [49].

In a more recent study, slow and gradual response to initial therapy has been shown to be a favourable prognostic factor in MM, with a significantly worse overall survival of early responders compared to late responders [50]. We see the same overall tendency. In the presented study, progressing patients displayed on average a clinical response kinetic with faster CR compared to the non-progressors.

Despite its importance, invasive BM sampling for routine monitoring of MRD has shortcomings by not accounting for spatial heterogeneity and the patchy nature of MM, which may lead to false-negative results. Moreover, undetectable MRD in the BM may hide extramedullary disease, potentially detectable by these technologies [51]. Additionally, it is an invasive procedure [52]. Alternative non-invasive methods for MRD testing, such as analysis of circulating tumour cells or circulating cell-free tumour DNA in liquid biopsies from PB [36, 37]. However, the sensitivity of MRD detection in PB and the optimal method to be used are unclear and further clinical studies are recommended to explore the use of PB for the detection of MRD and for comparison with results obtained in BM, in a similar way as shown for MM at diagnosis [53]. Finally, new sensitive methods, such as quantitative immunoprecipitation mass spectrometry and the MALDI TOF technique may overcome that shortcoming [54, 55].

In conclusion, this study emphasises that flow-MRD assessment is a sensitive and appropriate tool for deeper response evaluation in MM patients beyond CR, and for longitudinal monitoring of MRD with potential detection of early clonal expansion several months prior to biochemical and clinical progression. This offers the opportunity for early intervention and such strategies should be tested in clinical trials.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09184-1.

**Acknowledgements**
The authors honour Hans Erik Johnsen (1948–2018) for his tremendous work paving the way for the haematological precision medicine initiative at Aalborg University Hospital. The authors acknowledge the excellent technical assistance from Jane Ildal and Anja Führer in handling biobank samples, Helle Haholt and Louise H. Madsen for sample purification and flow cytometry acquisition assistance and Lise Tordrup Elkjær for administrative assistance. They acknowledge the participation of Anders Vik, Robert Brudevold, Karin C. Fosberg, Margaretha S. Carlsson and Olle Linder for participating in the study with sending a diagnostic sample. Foremost, we thank the patients who participated in the clinical protocols and the physicians, nurses and staff who cared for them.
Authors' contributions
A.S. acquired and processed the experimental data and performed the analysis. A.S. drafted the manuscript. H.J. initiated the study. H. J., A.W., P.G, and U.H.M discussed and adjusted the conception and design of study protocol. A.S., H.J., and K.D. were involved in planning the experimental setup. H.J. and K.D. supervised the experimental work. B.v.d.H. provided the clinical data. A.S. and R.F.B. performed the statistical calculations and designed the Figs. K.D., N.A., H.G, A.R., M.S., J.S.B. and M.B. aided in interpreting the results. N.F.A, M.H., P.G., U.C.F., C.H., H.G., N.A., D.S., F.H.S., L.A., U.H.M., N.G, A.W., B.A., B.L., E.H. and Y.H. contributed with patients used for the MRD study. All authors except H.J. critically reviewed the manuscript for intellectual content. The author(s) read and approved the final manuscript.

Authors’ information
A detailed list of participating sites and principal investigators for the flow-MRD study from the Nordic Myeloma Study Group appears in a supplement.

Funding
Research reported in this article was funded and supported by Den Obelske Familiefond and European Myeloma Network (EMN).

Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information file. All biological material has been used.

Declarations
Ethics approval and consent to participate
The study was approved by the national committees on health research ethics used.

All biological material has been

from all subjects.

The study was approved by the national committees on health research ethics

Ethics approval and consent to participate
The study was approved by the national committees on health research ethics and performed in accordance with the good clinical practice regulations and the declaration of Helsinki principles written informed consent was obtained from all subjects.

DK. VEH: H-1-2010-071/H-20006109.
SE: DNR: 653-10.
NO. REK 210/2344.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Haematology, Aalborg University Hospital, Forskningsens Hus, Søndre Skovvej 15, DK-9000 Aalborg, Denmark. 2Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 3Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 4For the Nordic Myeloma Study Group (NMSG) https://www.nordicmyeloma.org/. 5South Elvsborg Hospital, Boras, Sweden. 6Norwegian University of Science and Technology and St. Olavs University Hospital, Trondheim, Norway. 7Department of Haematology, University of Copenhagen, Copenhagen, Denmark. 8Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 9HOVON Data Center, Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 10Shane University Hospital, Lund, Sweden. 11Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. 12Department of Haematology, Sjælland Universityhospitalst, Roskilde, Denmark. 13Department of Hematology, Herlev Hospital, Herlev, Denmark. 14Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway. 15K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. 16Division of Hematology, Linköping University Hospital, Linköping, Sweden. 17NU Hospital Group, Uddevalla hospital, Uddevalla, Sweden. 18Sundby Hospital, Luleåa, Sweden. 19Department of Haematology, Stavanger University Hospital, Stavanger, Norway. 20Department of Haematology, Odense University Hospital, Odense, Denmark. 21For the European Myeloma Network (EMN) https://www.myeloma-europe.org/.

Received: 5 October 2021 Accepted: 7 January 2022 Published online: 05 February 2022

References
1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60 Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.1.2404.196.
2. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–21 Available from: http://www.nature.com/articles/leu2009174.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17975015.
4. Ravi P, Kumar SK, Cerhan JR, Maurer MI, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3).26. Available from: https://1038/s41408-018-0065-8.
5. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. Available from: https://1016/s1470-2045(16)30206-6.
6. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.
7. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48 [cited 2014 Oct 27] Available from: https://1016/s1470-2045(14)70442-5.
8. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31(36):4529–35.
9. Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015;29(10):2033–8 Available from: http://www.nature.com/articles/leu20151118.
10. Paiva B, Corchete LA, Vidriales M-B, Puig N, Maiso P, Rodriguez I, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896–907 Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-08-665679.
11. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Br J Haematol. 2016;173(1):186–96 Available from: http://www.nature.com/articles/leu201574.
12. Anderson KC, Auclair D, Kellogg GJ, Sigman CC, Avet-Loiseau H, Farrell AT, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–93.
13. Paiva B, Vidriales M-B, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica. 2009;94(11):1599–602 [cited 2011 Mar 7] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2770972&tool=pmcentrez&rendertype=abstract.
14. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540–7 [cited 2014 Oct 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23733781.
15. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99 Available from: http://ashpublications.org/
46. Mainou M, Madenidou A-V, Liakos A, Paschos P, Karagiannis T, Bekiari E, et al. Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. Eur J Haematol. 2017;98(6):563–8.

47. García de Veas Silva JL, Bermudo Guitarte C, Menéndez Valladares P, Rojas Noboa JC, Kestler K, Duro Millán R. Prognostic value of serum free light chains measurements in multiple myeloma patients. Lafrenie RM, PLoS One 2016;11(11):e0166841. Available from: https://doi.org/10.1371/journal.pone.0166841

48. Birol I, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intratumoral heterogeneity on myeloma outcome. Blood. 2014;123(22):3414–9 Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L373208920%5Cn10.1182/blood-2013-12-542662%5Cn.Http://www.ncbi.nlm.nih.gov/pubmed/24164531.

49. Schaar CG, Kluin-Nelemans JC, Le Cessie S, Franck PFH, Te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004;125(2):162–6.

50. Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019;3(19):2895–904.

51. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al. The mutational landscape of circulating tumor cells in multiple myeloma Europe PWC funders group. Cell Rep. 2017;19(1):218–24 Available from: http://michaellab.dfci.harvard.edu/publications/CellReports2017.pdf.

52. Gendron N, Chahabi SZ, Poinou G, Rivet N, Belleville-Rolland T, Lemaire P, et al. Pain assessment and factors influencing pain during bone marrow aspiration: a prospective study. PLoS One. 2019;14(8):1–13.

53. Sanoja-Flores L, Flores-Montero J, García JJ, Paiva B, Puig N, García-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117. Available from: https://doi.org/10.1038/s41408-018-0153-9.

54. Puig N, Mateos M-V, Conteras T, Paiva B, Cedena MT, Pérez JJ, et al. QpL-mass spectrometry in high risk smoldering multiple myeloma patients included in the GEM-CESAR trial: comparison with conventional and minimal residual disease IMWG response assessment. Blood. 2019;134(Supplement_1):581 Available from: https://ashpublications.org/blood/article/134/Supplement_1/581/426480/QpL-Mass-Spectrometry-in-High-Risk-Smoldering.

55. Evellard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, et al. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol. 2020;189(5):904–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.